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OBJECTIVES: Atrial fibrillation is the most common sustained arrhythmia and is associated with poor outcomes,
including stroke. The ability of anticoagulation therapy to reduce the risk of stroke has been well established;
however, the prevalence of anticoagulation therapy use in the Public Health System is unknown. The aim of this
study is to evaluate both the prevalence of anticoagulation therapy among patients with atrial fibrillation and
the indications for the treatment.
METHODS: In this cross-sectional study, we included consecutive patients who had atrial fibrillation
documented by an electrocardiogram performed between September 2011 and March 2012 at a university
hospital of the Public Health System. The variables analyzed included the risk of a thromboembolic event and/
or bleeding, the use of antiplatelet or anticoagulation therapy, the location where the electrocardiogram
report was initially reviewed and the specialty of the physician who initially reviewed it.
RESULTS: We included 162 patients (mean age 68.9 years, 56% men). Hypertension (90.1%), heart failure
(53.4%) and stroke (38.9%) were the most prevalent diseases found. Only 50.6% of the patients knew that they
had atrial fibrillation. Regarding the use of therapy, only 37.6% of patients classified as high risk according to
the CHADS2 scores and 35.5% according to the CHA2DS2VASc used oral anticoagulation. A presumptive
diagnosis of heart failure and the fact that the electrocardiogram was evaluated by a cardiologist were the only
independent predictors of the use of anticoagulants.
CONCLUSIONS: Our study found a low prevalence of oral anticoagulation therapy among patients with atrial
fibrillation and an indication for stroke prophylaxis for the use of this therapy, including among those with
high CHADS2 and CHA2DS2VASc scores.
KEYWORDS: Atrial Fibrillation; Stroke; Anticoagulation.
Bartholomay E, Polli I, Borges AP, Kalil C, Arroque A, Kohler I, et al. Prevalence of oral anticoagulation in atrial fibrillation. Clinics.
2014;69(9):615-620.
Received for publication on May 4, 2014; First review completed on May 4, 2014; Accepted for publication on May 27, 2014
E-mail: eduardo.bartholomay@gmail.com
& INTRODUCTION
Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia in clinical medicine, affecting approxi-
mately 1.5-2% of the population in developed countries (1-
5). In Brazil, it is estimated that approximately 1.5 million
individuals have AF and that AF is responsible for 33% of
all hospitalizations for arrhythmia. Moreover, AF is asso-
ciated with the occurrence of stroke and heart failure and
with an increase in total mortality (6). Although there
has been a decrease in the death rate associated with
cerebrovascular disease in Brazil over the past few decades,
stroke has persisted as the leading cause of death (7). For the
prevention of stroke, anticoagulant therapy was established
as the therapy of choice for the treatment of patients with
AF (8-10).
Anticoagulation therapy using vitamin K inhibitors
reduces the rate of stroke by 30% in high-risk patients,
indicated by CHADS2 or CHA2DS2VASc risk scores $2
(11-12). Recently, new anticoagulants, such as dabigatran,
rivaroxaban, apixaban and edoxaban have shown similar or
superior results in the prevention of stroke in AF patients
compared with warfarin (13-18). The consistent results of
anticoagulants have led to the classification of these drugs
as indication class I and evidence level A for the prevention
of embolic events in AF patients with CHADS2 or
CHA2DS2VASc scores $2, according to major guidelines
dedicated to this subject (4,6,14). However, despite recom-
mendations, studies conducted in developed countries have
shown that approximately 20-35% of AF patients with a
formal indication for anticoagulation do not use this therapy
(19-22). In Brazil in particular, so far, there are no data
regarding the use of anticoagulants in AF patients in the
Public Health System. Due to the high morbidity and
Copyright  2014 CLINICS – This is an Open Access article distributed under
the terms of the Creative Commons Attribution Non-Commercial License (http://
creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-
commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.
No potential conflict of interest was reported.
DOI: 10.6061/clinics/2014(09)07
CLINICAL SCIENCE
615
mortality associated with stroke, it is crucial to determine
the actual use of appropriate prophylactic therapy in this
patient population.
The main objective of our study was to evaluate the
prevalence of the use of anticoagulants among AF patients
who had a formal indication for stroke prophylaxis.
& MATERIALS AND METHODS
Population
The sample studied was provided by the University
Hospital ULBRA/Hospital Ma˜e de Deus (HU-HMD) in
Canoas, a city of 323,827 inhabitants located in the
metropolitan region of Porto Alegre, Rio Grande do Sul,
Brazil. The HU-HMD is a tertiary care institution respon-
sible for servicing the entire municipality and for reviewing
electrocardiograms (ECGs) from Basic Healthcare System
units.
All ECG reports interpreted at the HU-HMD between
September 1, 2011 andMarch 31, 2012, were initially analyzed.
These reports were obtained from the computerized system
of the institution. We included consecutive patients
whose ECGs showed AF. These patients were identified
using hospital registration forms and then contacted by
telephone. Those who agreed to participate, completed a
questionnaire about their medical condition. These data
were used to classify the patients according to thromboem-
bolic events (CHADS2 and CHA2DS2VASc) and bleeding
(HAS-BLED) (23) risk scores, the site of care and the use of
medications.
We excluded those individuals who did not respond to
three calls at different times, those who refused to
participate, those who did not clearly answer the questions
and those who had died.
The study was approved by the Ethics Committee of the
Lutheran University of Brazil and met the provisions of
Resolution 196 of the National Health Council.
Variables
Patients with CHADS2 or CHA2DS2VASc risk scores $2
were considered to have a formal indication for anticoagulant
therapy in the absence of contraindications, such as a history
of bleeding, blood dyscrasias or an allergy to anticoagulants.
Patients with a HAS-BLED risk score $3 were considered to
be at high risk for bleeding during anticoagulant therapy.
The specialty of the physician who requested and
evaluated the ECG and the location where the patient
performed clinical follow-up were determined.
Statistical analysis
Continuous variables are expressed as the mean and
standard deviation and Student’s t-test was used to assess
differences. Categorical variables are reported as percen-
tages and the differences between these variables were
evaluated by a chi-square or Fisher’s exact test, when
appropriate. The outcome-associated variables with a p-
value,0.10 or with clinical relevance were selected for
multivariate analysis. Logistic regression was then per-
formed to identify independent determinants of outcomes.
A p-value,0.05 was considered statistically significant. The
results are expressed as odds ratios and 95% confidence
intervals (CIs).
The analysis was performed with the Statistical Package
for Social Sciences (SPSS), version 20.0.
& RESULTS
Population characteristics
During the study period, 6,162 ECGs were interpreted,
295 of them (4.78%) showed AF. These ECGs belonged to
242 patients. Of the total sample, 52 patients (21.4%) could
not be found, 23 (9.5%) had died and 5 (2.06%) refused to
participate. Thus, 162 patients, representing 67.5% of the
initial sample, were ultimately included.
The evaluated patients were predominantly hypertensive
men aged .65 years. Nearly half of the patients already
knew that they had arrhythmia. The main characteristics of
the sample are described in Table 1.
Therapy and the risk of bleeding and
thromboembolic events
Table 2 illustrates the distribution of patients according to
risk scores. An analysis of CHADS2 and CHA2DS2VASc
scores showed that 87% and 95.7%, respectively, of patients
had scores $2 points.
Only 37.6% of patients with a CHADS2 score $2 used
anticoagulants. When stratified according to CHADS2 score,
approximately half of the patients with a CHADS2 score of 3
or 4 used anticoagulants, whereas only 15% of patients with
a CHADS2 score .5 used this therapy (Figure 1).
When the CHA2DS2VASc scores were analyzed, we ob-
served similar results; of the patients with a CHA2DS2VASc
Table 1 - Baseline characteristics.
Characteristic n = 162
Age (years) 68.94¡12
Gender (male) 92 (56.8)
Comorbidities
Hypertension 146 (90.1)
DM 44 (27.2)
CHF 88 (54.3)
Stroke 63 (38.9)
ACS 31 (19.1)
Alcohol use 12 (7.4)
Extracardiac vasculopathy 58 (35.8)
Renal disease 4 (2.5)
Liver disease 3 (1.9)
Known to have arrhythmia 82 (50.6)
Medications
ASA 80 (49.4)
Oral anticoagulant 55 (34)
First location where the ECG was reviewed
Basic unit 57 (35.2)
Secondary hospital 9 (5.6)
Tertiary hospital 51 (31.5)
Private clinic 5 (3.1)
Emergency department 17 (10.5)
Outpatient clinic 20 (12.3)
ECG was not checked 3 (1.9)
First doctor who reviewed the ECG
Generalist 56 (34.6)
Family physician 36 (22.2)
Cardiologist 40 (24.7)
Surgeon 5 (3.1)
Emergency physician 13 (8.0)
Neurologist 4 (2.5)
Other 5 (3.1)
ECG checked by a cardiologist at any time 84 (51.9)
The data are presented as the median¡ standard deviation or n (%). DM:
diabetes mellitus; CHF: chronic heart failure; ACS: acute coronary
syndrome; ASA: acetylsalicylic acid; ECG: electrocardiogram.
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score $2, only 35.5% had been adequately treated with
anticoagulants (Figure 2).
When we compared the two score types, we realized that
the CHA2DS2VASc score identified 3% of the patients as
belonging to the high-risk group, which would be classified
as moderate risk according to the CHADS2 score.
Regarding the use of antiplatelet agents, we observed that
25% of patients with a CHADS2 score of 0 and 61.5% of
patients with a score of 1 used this medication. However,
none of the patients with a CHA2DS2VASc score of 0 or 1
used antiplatelet therapy.
According to the HAS-BLED score, 34 patients (20.9%)
had a score $3, which suggested an increase in bleeding
risk with the use of oral anticoagulants. Of these patients, 12
(35%) used anticoagulant therapy.
Therapy recommendations based on the specialty
of the attending physician
Regarding the specialty of the physician who initially
reviewed the ECG revealing the patient’s AF diagnosis, we
noticed large variation in the percentage of patients with a
CHA2DS2VASc score $2 who were not using anticoagulant
therapy, ranging from 20.6% among those whose ECGs
were observed by cardiologists to 100% among those whose
ECGs were observed by surgeons or neurologists (p,0.01)
(Figure 3).
The location of the ECG review also showed large variation
based on the use of anticoagulants (p,0.01) (Figure 4).
When we analyzed only patients with a history of previous
ischemic stroke, we found that only 36.5% chronically used
oral anticoagulants.
Heart failure, hypertension, advanced age, diabetes and
prior stroke (CHADS2 factors), as well as the specialty of the
doctor who initially reviewed the ECG and the location
where the ECG was first reviewed, were used as variables
in a multivariate analysis. In this analysis, heart failure
(OR: 3.07, 95% CI: 1.35-7.00) and the fact the ECG was first
reviewed by a cardiologist versus a non-cardiologist (OR:
12.14: 95% CI: 4.85-30.37) were independent predictors of
anticoagulation.
& DISCUSSION
Our study has shown a low prevalence of oral anticoagulation
among patients with AF and an indication for the use of
this therapy based on risk scores. An Italian study
published in 2000 reported that anticoagulation rates were
approximately 70% for moderate-risk patients and greater
than 85% for high-risk patients (21). However, a study
published in 2002 showed rates closer to 60% for therapy
use in the U.S. population (22). The present study has
revealed that only 35% of our patients were on antic-
oagulants, which is a much lower prevalence than values
already reported for other countries. Furthermore, our
findings highlight the low prevalence (36.5%) of anticoagulant
use even in patients with a history of ischemic stroke.
Table 2 - Distribution of patients according to their
CHADS2, CHA2DS2VASc and HAS-BLED scores.
Score Score of risk (n (%))
CHADS2 CHA2DS2VASc HAS-BLED
0 8 (4.9) 2 (1.2) 7 (4.3)
1 13 (8.0) 5 (3.1) 48 (29.6)
2 50 (30.9) 12 (7.4) 73 (45.1)
3 39 (24.1) 40 (24.7) 31 (19.1)
4 29 (17.9) 24 (14.8) 3 (1.9)
5 15 (9.3) 33 (20.4) 0 (0.0)
6 8 (4.9) 25 (15.4) 0 (0.0)
7 - 15 (9.3)
8 - 6 (3.7)
Figure 1 - Prevalence of the use of oral anticoagulants according to the CHADS2 score.
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The risk scores used in our study have been widely
studied and validated and are directly related to the
occurrence of thromboembolic events. The CHADS2 score
determines a cumulative risk of stroke of less than 2% per
year for patients with a score of 0, of 4% per year for patients
with a score of 2 and of up to 18.2% per year for patients
with a score of 6 (11). The CHA2DS2VASc score, which was
recently incorporated into standard guidelines to more
accurately identify patients at moderate risk who would
most benefit from the use of anticoagulants, directly
correlates with the same outcomes. Additionally, the stroke
rate per year varies: 0% for those with a score of 0, 2.2% for
those with a score of 2, and 15.2% for those with a score of 9
(12).
The prevalence of AF in our study population was higher
than that found in other population-based studies. Whereas
the Anticoagulation and Risk Factors In Atrial Fibrillation
(ATRIA) study (24) showed a prevalence of 0.95% in the
general population and whereas other studies showed
values up to 1.49%, our data revealed a 4.78% prevalence,
possibly because our patients were selected solely based on
the indication for performing an ECG.
Regarding AF prevalence by sex and age our data are
similar to data found in the literature, with higher rates in
men of all age groups and with a gradual and proportional
increase with the aging of the population.
It is estimated that AF patients over 60 years old with no
structural heart disease present a cumulative risk of stroke
Figure 2 - Prevalence of the use of oral anticoagulants according to the CHA2DS2VASc score.
Figure 3 - Percentage of patients without anticoagulation therapy according to the specialty of the doctor who treated them.
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of 1.3% per year (6,25). This rate can be significantly reduced
with the proper use of anticoagulant therapy (26,27). In fact,
several studies published in recent decades have shown the
benefits of anticoagulation in patients with AF, with even
better results than those of antiplatelet agents (1-3). Based
on current guidelines, the non-indication of anticoagulants
in patients with AF and a high risk of thromboembolic
events can only be justified by a high risk of bleeding.
However, we found no relationship between HAS-BLED
bleeding scores and misuse of anticoagulants in our entire
study population.
In our study, the location where the patient was
monitored seemed to be directly related to misuse of oral
anticoagulants, with very low use in basic health units and
in private clinics. In contrast, patients in outpatient clinics at
a tertiary hospital (HU-HMD) showed a higher prevalence
of anticoagulation use when indicated. Another relevant
factor was the specialty of the attending physician, with
frequent prescription by cardiologists and very infrequent
or absent prescription by other specialties.
The most likely explanation for this difference in
anticoagulant use based on the location of monitoring may
be the difficulty of returning to the same health unit for a
dose adjustment of vitamin K inhibitors according to the
patient’s prothrombin time, causing the doctor to choose not
to prescribe anticoagulation therapy. This is especially an
issue for elderly patients, who often present with other
comorbidities, including a higher risk of falls (28), and reach
optimal anticoagulation levels at lower doses of vitamin K
inhibitors (29). Therefore, their care is more limited, which
may contribute to their doctors not prescribing treatments
that they cannot properly monitor.
The use of new anticoagulants that do not require
monitoring may help to improve this scenario; however,
these drugs are not yet available to the Public Health
System. Another potentially much more important factor
may be the unawareness of doctors about the importance of
this therapeutic intervention to prevent the mortality and
morbidity associated with stroke in AF patients.
& STUDY LIMITATIONS
Our study has important limitations. For example, the
prevalence of AF in the selected population may have been
underestimated because the diagnosis was made based on an
ECG and not based on continuous monitoring (such as via a
Holter monitor or loop recorder). Additionally, there were no
data on patients with paroxysmal AF who presented with
sinus rhythm on the ECG, for example. In particular, our
population was selected because the patients were participat-
ing in the Public Health System. We believe that our data
suggested a high prevalence of AF, chronic heart failure and
stroke, among other conditions, compared with the preva-
lence in other populations because when the patients sought
medical attention, they may have already been carriers of
certain changes that could motivate an ECG request.
The data obtained in this study may not represent the
whole of Brazil because the sample was limited to one
hospital and one municipality, although it is important to
note that the HU-HMD provides care to various levels of the
Public Health System. However, our analysis may have
incurred a measurement bias because the data were
collected by telephone. In addition, we have no data
regarding poor adherence. Thus, although anticoagulant
therapy was prescribed, certain patients may not have used
it. Considering the HAS-BLED score, it will be important to
evaluate the use of anticoagulant therapy in patients with a
high risk of bleeding, not only in the entire population but
also in groups stratified by the specialty of the physician
and the location where the ECG was first reviewed, given
that the present analysis was hampered by the small
number of patients within the groups.
Considering that AF is the most prevalent arrhythmia and
given the high morbidity and mortality associated with
stroke, it is possible that misuse of anticoagulants in this
population is a major public health problem associated with
the treatment of cardiac arrhythmias.
Our study found a low prevalence of oral anticoagulation
therapy among patients with AF and an indication for stroke
prophylaxis for the use of this therapy, including among those
with high CHADS2 and CHA2DS2VASc scores.
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